Literature DB >> 9243369

Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome.

R J Suhadolnik1, D L Peterson, K O'Brien, P R Cheney, C V Herst, N L Reichenbach, N Kon, S E Horvath, K T Iacono, M E Adelson, K De Meirleir, P De Becker, R Charubala, W Pfleiderer.   

Abstract

Previous studies from this laboratory have demonstrated a statistically significant dysregulation in several key components of the 2',5'-oligoadenylate (2-5A) synthetase/RNase L and PKR antiviral pathways in chronic fatigue syndrome (CFS) (Suhadolnik et al. Clin Infect Dis 18, S96-104, 1994; Suhadolnik et al. In Vivo 8, 599-604, 1994). Two methodologies have been developed to further examine the upregulated RNase L activity in CFS. First, photoaffinity labeling of extracts of peripheral blood mononuclear cells (PBMC) with the azido 2-5A photoaffinity probe, [32P]pApAp(8-azidoA), followed by immunoprecipitation with a polyclonal antibody against recombinant, human 80-kDa RNase L and analysis under denaturing conditions. A subset of individuals with CFS was identified with only one 2-5A binding protein at 37 kDa, whereas in extracts of PBMC from a second subset of CFS PBMC and from healthy controls, photolabeled/immunoreactive 2-5A binding proteins were detected at 80, 42, and 37 kDa. Second, analytic gel permeation HPLC was completed under native conditions. Extracts of healthy control PBMC revealed 2-5A binding and 2-5A-dependent RNase L enzyme activity at 80 and 42 kDa as determined by hydrolysis of poly(U)-3'-[32P]pCp. A subset of CFS PBMC contained 2-5A binding proteins with 2-5A-dependent RNase L enzyme activity at 80, 42, and 30 kDa. However, a second subset of CFS PBMC contained 2-5A binding and 2-5A-dependent RNase L enzyme activity only at 30 kDa. Evidence is provided indicating that the RNase L enzyme dysfunction in CFS is more complex than previously reported.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243369     DOI: 10.1089/jir.1997.17.377

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  15 in total

Review 1.  Chronic fatigue syndrome: probable pathogenesis and possible treatments.

Authors:  Birgitta Evengård; Nancy Klimas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

Review 3.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

Review 4.  A scientific journey through the 2-5A/RNase L system.

Authors:  Robert H Silverman
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

Review 5.  Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and the Safety of the Blood Supply.

Authors:  Andrew D Johnson; Claudia S Cohn
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

6.  Robert J. Suhadolnik (1925-2016).

Authors:  Paul W Doetsch
Journal:  J Interferon Cytokine Res       Date:  2016-05       Impact factor: 2.607

7.  RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome.

Authors:  Kiet Phong Tiev; Edith Demettre; Philippe Ercolano; Lionel Bastide; Bernard Lebleu; Jean Cabane
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

Review 8.  Diverse functions of RNase L and implications in pathology.

Authors:  Catherine Bisbal; Robert H Silverman
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

Review 9.  Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.

Authors:  Jesus Castro-Marrero; Naia Sáez-Francàs; Dafna Santillo; Jose Alegre
Journal:  Br J Pharmacol       Date:  2017-02-01       Impact factor: 8.739

Review 10.  The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome.

Authors:  Robert H Silverman; Carvell Nguyen; Christopher J Weight; Eric A Klein
Journal:  Nat Rev Urol       Date:  2010-06-01       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.